Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA issues blood centre/xenotransplant guidance:

This article was originally published in Clinica

Executive Summary

The US FDA has recommended that blood centres indefinitely defer collecting blood or plasma from recipients of a xenotransplant and their intimate contacts. The February 1 guidance document also contains recommendations on how to dispose of blood products manufactured from a donor who is discovered to have received a xenotransplant after the fact or to have been an intimate contact of a recipient of a xenotransplant. This is the second draft of the guidance document, altered to incorporate revisions based on public comments to the first draft published in the Federal Register on December 30 1999.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT064583

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel